Precipio’s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology NEW HAVEN, Conn., May 22, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a...

Chronic Myeloid Leukemia Market to Exhibit Significant Growth as Leading Companies Such as Novartis, Ascentage Pharma, Terns Pharmaceuticals, Sanofi, and Others are Exploring the Domain | DelveInsight New York, USA, March 23, 2023 (GLOBE NEWSWIRE) -- Chronic Myeloid Leukemia Market to Exhibit Significant Growth as Leading Companies Such as Novartis, Ascentage Pharma, Terns Pharmaceuticals,...

Global Chronic Myeloid Leukemia Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight Las Vegas, USA, May 23, 2022 (GLOBE NEWSWIRE) -- Global Chronic Myeloid Leukemia Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight  Chronic Myeloid Leukemia...

Global Chronic Myeloid Leukemia Treatment Market to Surpass US$ 10,864.9 Million by 2028, Says Coherent Market Insights (CMI) SEATTLE, April 08, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global chronic myeloid leukemia treatment market is estimated to be valued at US$ 7,216.3 million in 2021, and...

First quantitative diagnostic test validated for Treatment-Free Remission for Eligible Patients with Ph+ CML-CP Treated with Tasigna® Cleared by Health Canada PORTLAND, Ore. and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- MolecularMD Corporation received regulatory approval from Health Canada for the MRDx® BCR-ABL Test, a quantitative diagnostic...